Camp4 Therapeutics (CAMP) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on regulatory RNA-based therapeutics to upregulate gene expression for genetic diseases.

• Proprietary RNA Actuating Platform (RAP Platform) enables rapid identification of regulatory RNAs and development of antisense oligonucleotide (ASO) therapeutics.

• Lead candidate CMP-CPS-001 targets urea cycle disorders (UCDs); pipeline includes CNS and metabolic disease programs.

• Retains exclusive, worldwide rights to all product candidates and discovery programs.

Financial performance and metrics

• Net losses of $49.3M (2023) and $44.2M (2022); $25.0M loss for six months ended June 30, 2024.

• Accumulated deficit of $185.0M as of June 30, 2024.

• Cash and cash equivalents of $12.6M as of June 30, 2024.

• No product revenue to date; revenue from collaborations and licenses totaled $0.35M in 2023.

Use of proceeds and capital allocation

• Estimated net proceeds of $66.7M (or $77.1M if underwriters' option exercised) at $15.00/share IPO price.

• Proceeds to fund: (i) clinical development of CMP-CPS-001, (ii) advancement of CMP-SYNGAP, (iii) expansion of RAP Platform and preclinical programs, and (iv) working capital and general corporate purposes.

• Funds expected to support operations for at least 12 months post-offering; additional capital will be needed for full development and commercialization.